{"id":"W2095293611","doi":"10.1038/sj.bjc.6605972","title":"Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab","year":2010,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":85,"is_retracted":true,"has_abstract":true,"ca_institutions":"McGill University","funders":"National Institute of Environmental Health Sciences; National Institutes of Health; Pfizer","keywords":"Medicine; Internal medicine; Biomarker; Oncology; Lung cancer; Proportional hazards model; Carboplatin; Progression-free survival; Clinical trial; non-small cell lung cancer (NSCLC); Chemotherapy; Biology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":{"nature":"Retraction","reason":"Unreliable Results and/or Conclusions;","date":"12/4/2012 0:00","openalex_flagged":true},"screen":null}